Arthro Kinetics' Asian expansion gathers pace
This article was originally published in Clinica
Arthro Kinetics (Esslingen, Germany) has made further progress in the Asian orthopaedics market by signing what the company has said to be the first major deals to commercialise its CaReS biologic cartilage regeneration products in the region. The orthopaedic regeneration product company this week inked an agreement with its joint venture partner, Arthro Anda Tianjin Biologic Technology to sell the product line in China, Taiwan and Hong Kong. The joint venture, of which Arthro Kinetics owns around 15%, was established in September 2006 for the production of CaReS using Arthro Kinetics' proprietary 3D collagen matrix for the surgical treatment of large area damage to the knee joint. The manufacturing facility, based in Tianjin, China, is scheduled to open at the end of 2008.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.